Balance Therapeutics Inc.
Balance Therapeutics Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Balance Therapeutics Inc..
Balance Therapeutics Inc. is a company.
Key people at Balance Therapeutics Inc..
Key people at Balance Therapeutics Inc..
Balance Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for debilitating neurological conditions, with a focus on sleep disorders, cognitive deficits, and intellectual disabilities.[1][2][3] Headquartered in Burlingame, California, the company targets high unmet medical needs by modulating neurobiological pathways, such as restoring synaptic balance between inhibition and excitation to enhance brain plasticity.[1][4] It serves patients and families affected by these conditions, addressing problems like impaired cognition and intellectual disabilities through innovative drug candidates, backed by an experienced drug development team committed to advancing life-improving medicines.[1][3]
Founded in 2009 with around 4-6 employees and approximately $3 million in annual revenue as of 2025, Balance has pursued R&D in biotechnology and pharmaceuticals, including clinical trials and drug discovery.[2]
Balance Therapeutics spun out of Stanford University as an R&D-focused company targeting therapeutics for intellectual disabilities and related neurological conditions.[3] Established in 2009 in Burlingame, California, it emerged from academic research on brain plasticity and synaptic function, aiming to develop drugs that could potentially raise IQ or improve cognitive outcomes in syndromes like those involving intellectual disability.[2][3][4]
A pivotal early moment came in 2015 when the company raised $18 million to fund clinical trials for its lead approach, which seeks to restore excitatory-inhibitory balance in synapses.[4] This funding underscored initial traction in biotechnology investment circles, positioning Balance as a Stanford-derived innovator in neuropharmacology.[3][4]
Balance Therapeutics rides the wave of neuroscience and biotechnology advancements in brain plasticity, cognitive enhancement, and precision neurology, amid growing demand for treatments in intellectual disabilities and sleep disorders.[1][3][4] Its timing aligns with market forces like rising neuropharma investments and FDA interest in rare neurological indications, where synaptic modulation offers novel solutions absent in traditional therapies.[1][2][4]
As a Stanford spinout, it contributes to the biotech ecosystem by translating academic research into clinical assets, influencing startup dynamics in California's pharma hub and supporting the shift toward plasticity-focused drugs for neurodevelopmental conditions.[3][4]
Balance Therapeutics is poised to advance its pipeline toward later-stage trials or partnerships, potentially targeting FDA approvals in cognitive and sleep therapeutics amid expanding neurobiotech funding.[1][2][4] Trends like AI-driven drug discovery and personalized neurology could accelerate its synaptic modulation platforms, while market growth in intellectual disability treatments may boost its valuation and influence.[3][4]
With Pappas Capital backing and a focused team, expect evolution toward commercialization or acquisition, solidifying its role in delivering brain health innovations that began with Stanford's plasticity insights.[1][3]
